Gain Therapeutics
Market cap $52.5M 44.5M shares (10-Q, Oct 30, 2026) × $1.18 close Nov 17, 2026
Most recent annual filing: 2026-03-15
- GT-02287 Ph2 start1Q 2027GT-02287 Ph2 start, 1Q 2027, material
- Cash runway corporate update2Q 2027Cash runway corporate update, 2Q 2027, routine
Bar width shows how precise the guidance is — a pin is a stated date, a wide band a six-month window. Deeper blue means more of the thesis rides on the event; it is not a view on the stock.
Pipeline (5 active programs)
GT-02287
GT-04686
Technology platforms
Magellan · Minoryx Therapeutics
Computational target and drug discovery platform using AI-driven structure-based virtual screening to identify novel allosteric binding sites on disease-implicated proteins and discover proprietary small molecule structurally targeted allosteric regulators (STARs). Disease focus areas include CNS disorders, lysosomal storage disorders, metabolic disorders, and oncology.
Magellan
Proprietary allosteric drug discovery platform enabling identification of novel small molecule modulators that restore or disrupt protein function; disease focus includes neurodegenerative diseases, rare genetic disorders (lysosomal storage disorders), and oncology
Targets: GCase, β-galactosidase, GBA1
Capital (as filed)
- Cash
- $11.7M cash and cash equivalents · Sep 30, 2026 (10-Q)
- Operating cash flow
- −$3.0M quarter Jun 30, 2026 → Sep 30, 2026, year-to-date difference (10-Q)
- As stated in coverage
- $11.7M cash, runway second quarter of 2027 per the update of Nov 10, 2026 — the company's own words as read there, not the filed figure
Cash, investments and operating cash flow are the company's own XBRL facts as filed with the SEC, each shown with its period end and tag. As-stated figures come from the company's own words as read in Biotech Distilled coverage, dated, and routinely count securities and planned financing that a balance sheet does not. Offering rows are the SEC cover pages as filed. Not investment advice. Figures as of Nov 18, 2026.
Biotech Distilled coverage (14)
- 2026-11-11 UPDATE: Gain Therapeutics (GANX) - The Lawsuit Survives, The Lab Goes Quiet 🔒 Paid
- 2026-10-01 UPDATE: Gain Therapeutics (GANX) - Stable Scores, Vanishing Gap, Slipped Start 🔒 Paid
- 2026-09-29 UPDATE: Gain Therapeutics (GANX) - The CEO Takes the Checkbook 🔒 Paid
- 2026-08-12 UPDATE: Gain Therapeutics (GANX) - Day 360 Durability, and a $13.1M Problem 🔒 Paid
- 2026-07-16 UPDATE: Gain Therapeutics (GANX) - The Shareholder Letter, The Rebrand, and the CMO Exit
- 2026-06-29 UPDATE: Gain Therapeutics (GANX) - The FDA Clears the IND 🔒 Paid
- 2026-05-26 UPDATE: Gain Therapeutics (GANX) - The Stratification Gap Just Narrowed 🔒 Paid
- 2026-05-12 UPDATE: Gain Therapeutics (GANX) — The Dilution Engine Hums On, The Clock Keeps Ticking 🔒 Paid
- 2026-03-27 UPDATE: Gain Therapeutics (GANX) - The 10-K Unveils the Dilution Engine... 🔒 Paid
- 2026-03-21 UPDATE: Gain Therapeutics (GANX) - The Update That Spooked the Market
- 2026-03-14 UPDATE: Gain Therapeutics (GANX) - The FDA Taps the Brakes 🔒 Paid
- 2026-02-07 UPDATE: Gain Therapeutics (GANX) - The "Missing" Data Has Been Found (And It Looks Pretty Good) 🔒 Paid
- 2025-12-22 UPDATE: Gain Therapeutics (GANX) – Explaining The Rebound After The CEO’s Defense
- 2025-12-19 Gain Therapeutics (GANX): Scientific Due Diligence for Lead and Pipeline Products
Articles open on Substack. Some are subscriber-only; those marked ★ Distilled Pro are for Distilled Pro members.
Verdict history (14 calls)
Every verdict Biotech Distilled has published on Gain Therapeutics, oldest first — the full history, never a selection. How calls are scored: the track record.
- 2025-12-19 Watch Gain Therapeutics (GANX): Scientific Due Diligence for Lead and Pipeline Products Biomarker data validates mechanism but dilution overhang and missing functional data warrant waiting for dust to settle before entering.
- 2025-12-22 Speculative buy speculative UPDATE: Gain Therapeutics (GANX) – Explaining The Rebound After The CEO's Defense CEO's embargo explanation and CDA mention credibly reduce corporate risk and suggest a strategic partnership reveal could be a major catalyst.
- 2026-02-07 Buy core UPDATE: Gain Therapeutics (GANX) - The "Missing" Data Has Been Found (And It Looks Pretty Good) Smoking-gun stratification slide shows statistically significant motor improvement in high-GluSph patients, de-risking Phase 2 and validating the precision-medicine thesis.
- 2026-03-14 Hold UPDATE: Gain Therapeutics (GANX) - The FDA Taps the Brakes FDA request for additional preclinical data re-elevates regulatory and corporate risk, warranting caution before the IND is cleared.
- 2026-03-21 Hold UPDATE: Gain Therapeutics (GANX) - The Update That Spooked the Market Biological thesis intact but FDA overhang, cash void, and backup-compound hype signal corporate and chemical risks flashing red.
- 2026-03-27 Hold UPDATE: Gain Therapeutics (GANX) - The 10-K Unveils the Dilution Engine... 10-K confirms massive ATM dilution funded the runway, FDA IND clearance slipped to Q2, and a new CEO lawsuit adds corporate risk, making aggressive buying premature.
- 2026-05-12 Hold UPDATE: Gain Therapeutics (GANX) — The Dilution Engine Hums On, The Clock Keeps Ticking Going-concern warning returned, ATM selling accelerating into weakness, and FDA IND still pending; wait for clearance before getting constructive.
- 2026-05-26 Hold UPDATE: Gain Therapeutics (GANX) - The Stratification Gap Just Narrowed Stratification gap narrowed from 6.7 to 4.8 points, softening the precision-medicine thesis, while FDA IND and corporate risks remain unresolved.
- 2026-06-29 Buy core UPDATE: Gain Therapeutics (GANX) - The FDA Clears the IND FDA authorized the Phase 2 IND without a clinical hold, retiring the key regulatory tail risk and restoring a tradeable catalyst path toward Phase 2a start.
- 2026-07-16 Buy core UPDATE: Gain Therapeutics (GANX) - The Shareholder Letter, The Rebrand, and the CMO Exit Regulatory de-risking from IND clearance intact; CMO exit is awkwardly timed but not thesis-breaking, and runway extended one quarter.
- 2026-08-12 Buy core UPDATE: Gain Therapeutics (GANX) - Day 360 Durability, and a $13.1M Problem High-GluSph durability signal extended to Day 270/360 without collapsing, but cash fell to $13.1M with going-concern language and accelerating ATM dilution making patience warranted.
- 2026-09-29 Hold UPDATE: Gain Therapeutics (GANX) - The CEO Takes the Checkbook CFO departure leaves CEO—a named defendant in fraud suit—holding the finance function two weeks before the critical Korea readout, worsening corporate risk enough to step back from BUY.
- 2026-10-01 Avoid UPDATE: Gain Therapeutics (GANX) - Stable Scores, Vanishing Gap, Slipped Start Korea readout showed the high-GluSph responder edge faded to 'everyone is stable,' Phase 2 slipped two quarters requiring a new protocol, and cash runway doesn't fund the trial it's supposed to start.
- 2026-11-11 Avoid UPDATE: Gain Therapeutics (GANX) - The Lawsuit Survives, The Lab Goes Quiet Fraud claim against CEO survived dismissal, ATM selling at new lows near $1.58, R&D cut by half before Phase 2, and Phase 2 protocol being comprehensively redesigned with no responder signal to anchor it.
- Long call · opened Dec 22, 2025 at $3.19 · closed Oct 2, 2026 (flipped bearish (avoid)) at $1.71 · -46.4% vs XBI +22.7%
- Avoid call · opened Oct 2, 2026 at $1.71 · -31.0% vs XBI -5.9% (Nov 17, 2026)
Every verdict Biotech Distilled has published on this company, in order, with the post it came from — the full history, never a selection. Position figures are the same ones shown on /track-record, computed by the same method. Editorial opinion, not investment advice.
Timing, in the company's words (3 quotes from 3 filings)
Sentences quoted verbatim from the company's SEC filings, newest filing first. Each sits under the filing it appeared in; the "matched to" tag names the calendar row it was read for.
-
-
“The Company expects to submit the protocol for approval during the fourth quarter of 2026 on track to initiate the study in the first quarter of 2027.”
matched to GT-02287 · trial initiation
-
-
-
“We expect to complete Part 2 of the Phase 1b study in October 2026.”
matched to GT-02287 · trial initiation / matched to GT-02287 · readout other
-
-
-
“We expect to complete Part 2 of the Phase 1b study in October 2026.”
matched to GT-02287 · readout other
-
Timing sentences quoted from the company's own SEC filings, each under the filing it appeared in. The 'matched to' tag is the calendar row the sentence was read for; the filing is the source. Not investment advice.
Filings & releases (34)
SEC filings from EDGAR and press releases captured from the company's investor-relations site, newest first. Releases captured from Apr 24, 2026; filings from March 2026. Summaries come from the BD update that read the document; "BD extracted" counts point at the pipeline table above. All companies →
- Nov 17, 2026ReleaseGain Therapeutics Presents Clinical Data from Phase 1b Study of Rexaceract and Preclinical Data from Novel GCase Modulator GT-04686
- Nov 17, 20268-KCurrent report: other events
- Nov 10, 2026ReleaseGain Therapeutics Reports Financial Results for Third Quarter 2026 and Provides Corporate Update→ BD updateSummary on the 8-K
- Nov 10, 20268-KCurrent report: results of operations · EX-99.1→ BD updateThe Schwartzberg motion-to-dismiss denial puts the CEO fraud lawsuit into active discovery — a new escalation not in any prior post — while cash hits $11.7M, the ATM prints at $1.58, and the stock is down 37% since the October Korea readout.
- Nov 10, 202610-QQuarterly report→ BD updateSummary on the 8-K
- Nov 5, 2026ReleaseGain Therapeutics Announces Late-Breakers and Poster Presentations at Upcoming Scientific Conferences
- Oct 28, 20268-KCurrent report: officer / director change
- Oct 8, 2026ReleaseGain Therapeutics to Attend the 2026 Maxim Growth Summit
- Oct 1, 2026ReleaseGain Therapeutics Presents Positive Phase 1b Open-Label Extension Data For Rexaceract Demonstrating Further Evidence of Disease-Modifying Activity Through 12 Months Administration→ BD updateSummary on the 8-KBD extracted 1 program update from this document → GANX pipeline
- Oct 1, 20268-KCurrent report: other events→ BD updateThe 12-month Phase 1b extension data for rexaceract lands at the Korea Movement Disorders Congress: motor scores stable across all participants with no clinically meaningful progression, but the Phase 2 start has slipped a full two quarters to Q1 2027 — and the precision-medicine stratification story just got complicated.
- Sep 29, 2026ReleaseGain Therapeutics Announces Poster Presentation at International Congress of Parkinson’s Disease and Movement Disordersvia aggregator
- Sep 28, 20268-KCurrent report: officer / director change→ BD updateGANX's CFO just resigned, effective September 30 — leaving CEO Gene Mack as interim CFO, principal financial officer, and principal accounting officer simultaneously, just weeks before the make-or-break October Phase 1b readout and with going-concern language still on the books.
- Sep 17, 2026ReleaseGain Therapeutics to Participate at ROTH Fifth Annual Healthcare Opportunities Conference
- Aug 25, 2026ReleaseGain Therapeutics to Participate at H.C. Wainwright 28th Annual Global Investment Conference
- Aug 11, 2026ReleaseGain Therapeutics Reports Financial Results for Second Quarter 2026 and Provides Corporate UpdateBD extracted 2 program updates from this document → GANX pipeline
- Aug 11, 20268-KCurrent report: results of operations · EX-99.1
- Aug 11, 202610-QQuarterly report
- Jul 16, 2026ReleaseGain Therapeutics CEO Gene Mack Issues Letter to Shareholders and Provides Operational UpdateBD extracted 1 program update from this document → GANX pipeline
- Jul 16, 20268-KCurrent report: other events
- Jun 29, 2026ReleaseGain Therapeutics Receives FDA Clearance of IND to Advance GT-02287 into Phase 2 Clinical Development for Parkinson’s Disease
- Jun 29, 20268-KCurrent report: other events
- Jun 25, 20268-KCurrent report: shareholder vote
- Jun 10, 2026ReleaseGain Therapeutics to Present at H.C. Wainwright 7th Annual Neuro Perspectives Expert Summit
- May 26, 2026ReleaseGain Therapeutics Presents Positive Interim Data from Phase 1b Clinical Study of GT-02287 at 3rd International GBA1 Meeting 2026
- May 26, 20268-KCurrent report: other events
- May 11, 2026ReleaseGain Therapeutics Reports Financial Results for First Quarter 2026 and Provides Corporate Update
- May 11, 20268-KCurrent report: results of operations · EX-99.1
- May 11, 202610-QQuarterly report
- Apr 28, 2026DEFA14AProxy soliciting material
- Apr 28, 2026DEF 14AProxy statement
- Apr 24, 2026ReleaseGain Therapeutics Announces Oral Presentation at 3rd International GBA1 Meeting 2026
- Mar 26, 20268-KCurrent report: results of operations · EX-99.1
- Mar 26, 202610-KAnnual report
- Mar 18, 20268-KCurrent report: Reg FD disclosure, other events · EX-99.1 EXHIBIT 99.1
1 more filing (13G holder notices, S-8, proxy material, SEC correspondence …)
- Apr 28, 2026ARSAnnual report to shareholders